Health

FDA approves Merck’s RSV shot for babies despite 11.71% serious adverse reactions

The following information is from Children’s Health Defense. The FDA has approved Merck’s RSV antibody injection for newborns and infants, to be marketed under the name Enfanzia. The one-time shot, known scientifically as clesrovimab, is Merck’s direct competitor to Sanofi and

FDA approves Merck’s RSV shot for babies despite 11.71% serious adverse reactions Read More »

(READ) Comer opens hearing on privacy, national security risks in 23andMe bankruptcy sale

The following is from the House Oversight Committee Republicans. House Committee on Oversight and Government Reform Chairman James Comer (R-Ky.) opened a full committee hearing on “Securing Americans’ Genetic Information: Privacy and National Security Concerns Surrounding 23andMe’s Bankruptcy Sale.” Comer

(READ) Comer opens hearing on privacy, national security risks in 23andMe bankruptcy sale Read More »

Scroll to Top